← Back to Home

Lilly plans to acquire Merida for up to $2.875 billion, betting on therapies that remove disease-causing antibodies

Merida aims to change how autoimmune diseases are treated, moving from suppressing symptoms to directly removing the antibodies that drive disease. Lilly’s acquisition agreement brings resources to this development approach, but the lead drug remains in Phase 1 trials, and early signs of antibody reduction have yet to translate into clinical benefits.

By SURL BioNews

When antibodies drive disease, can they be precisely removed while preserving the body’s existing immune defenses? This is the therapeutic approach Merida Biosciences is exploring. On August 31, 2026, Eli Lilly announced that it had signed a definitive agreement to acquire the biotech company, preparing to incorporate its disease-causing antibody degradation platform into its research and development efforts for autoimmune and allergic diseases.

The transaction is valued at up to $2.875 billion, payable in cash, including an upfront payment and milestone payments contingent on specified conditions. The full amount will therefore not be paid immediately after signing. Merida’s legal adviser, Goodwin, also confirmed these terms. At the time, the parties expected the transaction to close in the fourth quarter of 2026, subject to regulatory approval and other customary conditions. The upfront payment amount and milestone details have not been disclosed.

Merida’s central concept is to use engineered biologics to selectively degrade disease-causing autoantibodies. These antibodies are part of the immune system but may mistakenly act against the body’s own tissues. The company aims to preserve normal immune function while removing the factors that cause disease. This remains a design goal requiring validation in clinical trials and cannot be considered an established therapeutic advantage.

Its lead drug candidate, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease. In Graves’ disease, specific autoantibodies activate the thyroid-stimulating hormone receptor, prompting the thyroid to produce excessive amounts of hormones. Thyroid eye disease may cause eye inflammation, bulging eyes, double vision, and impaired vision. MER511 aims to intervene in this disease-causing chain by directly removing the relevant antibodies.

Lilly said preliminary Phase 1 data showed that MER511 could substantially reduce disease-causing thyroid-stimulating antibodies and demonstrated a favorable early safety profile. However, the acquisition announcement did not provide the number of participants, the magnitude of antibody reduction, the follow-up duration, or complete adverse event data. Antibody reduction offers an early indication of the drug’s activity, but further validation is needed to establish whether it improves symptoms, whether its effects persist, and whether long-term use is safe.

The development pipeline also extends to other antibody-driven diseases. MER769 remains at the preclinical stage, with development targeting food allergies, asthma, and chronic spontaneous urticaria. There are also earlier-stage programs for membranous nephropathy and other conditions. These programs give the acquisition significance beyond a single drug, while also indicating that evidence for the platform’s effectiveness across diseases must still be established individually.

A Reuters report published by The Economic Times placed the transaction within Lilly’s strategy to expand its business beyond obesity and diabetes. For Lilly, acquiring Merida represents an investment in a therapeutic approach that remains at an early stage. For patients, meaningful progress will depend on whether subsequent trials can demonstrate that removing disease-causing antibodies produces sustained, measurable improvements in health.

References

  1. pharma.economictimes.indiatimes.com
  2. Goodwin